Markus Magerl, MD

Markus Magerl, MD, from Charité-Universitätsmedizin Berlin.

Articles by Markus Magerl, MD

HAE in 2026: New Therapies, Updated Guidelines, the Case for Early Treatment

ByMauro Cancian, MD, PhD,Markus Magerl, MD,Aleena Banerji, MD

May 11th 2026

Experts weigh in on a rapidly evolving treatment landscape, from a first-line oral option to a one-time CRISPR therapy showing 87% attack reduction.

BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD

ByMarkus Magerl, MD

March 10th 2026

At AAAAI 2026, Magerl discusses phase 2 data showing BW-20805 reduced hereditary angioedema attacks by up to 100% with dosing intervals of up to 6 months.

Latest Updated Articles

BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD
March 10th 2026
HAE in 2026: New Therapies, Updated Guidelines, the Case for Early Treatment
May 11th 2026

Markus Magerl, MD

Articles by Markus Magerl, MD

HAE in 2026: New Therapies, Updated Guidelines, the Case for Early Treatment

BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD

Latest Updated Articles

Trending on HCPLive

Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial

Sutezolid Shows Promise as Safer Oxazolidinone in Novel 4-Month TB Regimen

Tezepelumab Reduces Severe Asthma Exacerbations by 70% in Phase 4 PASSAGE

twiist AID System Improves HbA1c, Time in Range in Insulin-Treated Type 2 Diabetes

Q&A: How Does the Current HS Landscape Look? With Kiera Booth, MD